| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7014846 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US7459151 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5496545 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US6509013 | GENZYME | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US6858203 | GENZYME | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5667775 | GENZYME | Phosphate-binding polymers for oral administration |
Sep, 2014
(9 years ago) | |
| US9095509 | GENZYME | Sachet formulation for amine polymers |
Dec, 2030
(6 years from now) | |
Renvela is owned by Genzyme.
Renvela contains Sevelamer Carbonate.
Renvela has a total of 7 drug patents out of which 6 drug patents have expired.
Expired drug patents of Renvela are:
- US7014846
- US7459151
- US5496545
- US6509013
- US6858203
- US5667775
Renvela was authorised for market use on 18 February, 2009.
Renvela is available in for suspension;oral dosage forms.
Renvela can be used as phosphate binding.
The generics of Renvela are possible to be released after 06 December, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 25, 2019 |
| New Dosage Form(NDF) | Aug 12, 2012 |
Drugs and Companies using SEVELAMER CARBONATE ingredient
Market Authorisation Date: 18 February, 2009
Treatment: Phosphate binding
Dosage: FOR SUSPENSION;ORAL
RENVELA family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7459151 | SANOFI | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US7014846 | SANOFI | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US6509013 | SANOFI | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5496545 | SANOFI | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US6858203 | SANOFI | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5667775 | SANOFI | Phosphate-binding polymers for oral administration |
Sep, 2014
(9 years ago) | |
| US7985418 | SANOFI | Aliphatic amine polymer salts for tableting |
Oct, 2025
(1 year, 5 months from now) | |
Renvela is owned by Sanofi.
Renvela contains Sevelamer Carbonate.
Renvela has a total of 7 drug patents out of which 6 drug patents have expired.
Expired drug patents of Renvela are:
- US7459151
- US7014846
- US6509013
- US5496545
- US6858203
- US5667775
Renvela was authorised for market use on 19 October, 2007.
Renvela is available in tablet;oral dosage forms.
Renvela can be used as phosphate binding.
The generics of Renvela are possible to be released after 27 October, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 25, 2019 |
Drugs and Companies using SEVELAMER CARBONATE ingredient
Market Authorisation Date: 19 October, 2007
Treatment: Phosphate binding
Dosage: TABLET;ORAL
RENVELA family patents